Is Faster Always Better? Ultra-Fast-Track Versus Fast-Track Extubation in Adult Cardiac Surgery: A Comprehensive Meta-analysis With Meta-regression.

J Cardiothorac Vasc AnesthJun 11, 2026 (epub)
Clinical ResearchCardiologyCardiothoracic Surgery

Kristine Santos, Neel Patel, Takumi Umibe et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis compared ultra-fast-track extubation (UFTE) to fast-track extubation (FTE) in nearly 800,000 adult cardiac surgery patients. UFTE was associated with lower 30-day mortality (OR, 0.54), shorter ICU stay (MD, -12.27 hours), and reduced hospital stay (MD, -1.19 days). The study design was a systematic review and meta-analysis.

Key findings

  • UFTE was linked to a 30-day mortality odds ratio of 0.54.
  • ICU length of stay was reduced by an average of 12.27 hours with UFTE.
  • Hospital length of stay decreased by 1.19 days with UFTE.
  • The stroke rate was lower with UFTE, with an odds ratio of 0.85.

Why it matters

Understanding the benefits of UFTE over FTE can help clinicians optimize recovery protocols in cardiac surgery, potentially leading to shorter hospital stays and improved patient outcomes.

Source

PubMed · PMID 42469073

Published in J Cardiothorac Vasc Anesth. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.